CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,036,294 enrolled
Drug / intervention
Menopausal hormone therapy Intervention Type: Drugdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06033521
NCT06033521N/ACompleted

Treatment Patterns of Menopausal Hormone Therapy in South Korea: a Nationwide Cohort Study

Pfizer·observational·Posted Sep 13, 2023·Updated Apr 18, 2025

In Brief

An observational study evaluating Menopausal hormone therapy Intervention Type: Drug for Menopause and Bone Demineralization. Completed, enrolled 1,036,294 participants across 1 site.

Detailed Summary

The purpose of this study is to learn about how the commonly used menopausal hormone therapies were prescribed and taken in practice. This is done by using healthcare database, to study the overall dangers and benefits of menopausal hormone therapies in real-world practice. This study will include subjects who were newly diagnosed menopausal symptoms between 2012 and 2019. They were all followed up for 12 months at least. The study included the below subjects who: * were aged 40-59 years * were diagnosed to have menopausal symptoms through some medical check-ups The data collected will be used to understand: * how the commonly used menopausal hormone therapies were prescribed and taken in practice * how patients took medication as prescribed by their doctors This might help to understand treatment trends of these therapies.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesSouth Korea
Collaborators--

Timeline

N/ACompletedFinished
202420252026
First PostedSep 13, 2023
Enrollment StartSep 12, 2023
Primary CompletionMar 11, 2024
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 2.8 years ago

Interventions

Menopausal hormone therapy Intervention Type: Drugdrug

Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database